Original Article

Evaluation of the efficacy of Niosomal Curcumin Nanoformulation in Cancer therapy

Ashraf Alemi , Mohammad Farrokhifar, Mojtaba Haghi Karamallah, Majid Farrokhifar, Zakieh Entezari Nasab, Ali Farrokhifar

Ashraf Alemi
Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Email: alemi.ashraf@gmail.com

Mohammad Farrokhifar
Kar Higher Education Institute, Rafsanjan, Iran

Mojtaba Haghi Karamallah
Biotechnology Research Center, International Campus, Shahid Sadoughi University of Medical Science, Yazd, Iran

Majid Farrokhifar
Department of Pediatrics, Sabzevar University of Medical Sciences, Sabzevar, Iran

Zakieh Entezari Nasab
Department of Pediatrics, Semnan University of Medical Sciences, Semnan, Iran

Ali Farrokhifar
Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran
Online First: September 28, 2017 | Cite this Article
Alemi, A., Farrokhifar, M., Haghi Karamallah, M., Farrokhifar, M., Entezari Nasab, Z., Farrokhifar, A. 2017. Evaluation of the efficacy of Niosomal Curcumin Nanoformulation in Cancer therapy. The Cancer Press 3(3): 77-85. DOI:10.15562/tcp.53


During the past decade vesicles as a tool to improve drug delivery, has created a lot of interest amongst the scientist working in the area of drug delivery systems. Based on their biodegradable, biocompatible and nonimmunogenic structure, niosomes are promising drug carriers that are formed by self-assembly of nonionic surfactants and cholesterol in an aqueous phase. Curcumin (Cur),  a natural polyphenol found in Curcuma longa, has been utilized in multiple medicinal areas from antibiotic to antitumor treatment. However, the chemical structure of curcumin results in poor stability, low solubility and rapid degradation in vivo, limiting its clinical utilization. To address these problems, we have prepared a niosome system composed of nonionic surfactants polyoxyethylene sorbitan monostearate and cholesterol by thin film hydration method. The niosomal curcumin was evaluated for anti-cancer efficacy in prostate cancer cell line (PC-3) by MTT assay. Cur was encapsulated in the niosomes with a high entrapment efficiency of 98.4 ± 0.4%. Average particle size was found to be 127.5 ± 1.2 nm. Niosomal curcumin (Nio -Cur)  exhibited enhanced cytotoxic activity against PC-3 cells compared with free Cur. These results demonstrated that the Nio -Cur system is a promising strategy for the delivery of Cur and prostate cancer therapy.

 

No Supplementary Material available for this article.
Article Views      : 64
PDF Downloads : 17